Clinical trials: Primary Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Hypermetabolism in ALS Using Six REE Formulas
Introduction: About 50-60% of Amyotrophic Lateral Sclerosis (ALS) is characterized by hypermetabolism, defined as 10% or more excess resting energy expenditure (REE) compared to theoretical values.
- Trial name
- NCT03382392
- Testing
- Assesment of REE in ALS patients compared to control populations and to compare six formulas commonly used to predict REE.
- Where
- France
- Volunteers
- 449 people
- Sponsor
- University Hospital, Limoges
Amyotrophic Lateral Sclerosis
Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS)
This study is designed to evaluate whether a combination of N-acetylcysteine (NAC) and EH-301 can slow down or improve symptoms of amyotrophic lateral sclerosis (ALS).
- Trial name
- NADALS-001-ALS (NCT07414212)
- Testing
- Acetylcysteine, EH301, Riluzole
- Where
- Spain
- Volunteers
- 90 people
- Sponsor
- Biogipuzkoa Health Research Institute
Amyotrophic Lateral Sclerosis
Application of Motor Unit Estimation Index in Amyotrophic Lateral Sclerosis and Related Diseases
This was a cross-sectional study in which patients were divided into 20 patients with amyotrophic lateral sclerosis, 20 patients with peroneal muscular dystrophy, 20 patients with Kennedy's disease and 30 healthy controls, in…
- Trial name
- NCT04956822
- Testing
- Basic information, Functional scores, MINUX
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Peking University Third Hospital
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS), or "Lou Gehrig's Disease", is a fatal disorder that causes progressive degeneration and weakening of the muscles of breathing, leading to breathing insufficiency and eventually breathing…
- Trial name
- NCT00537446
- Testing
- noninvasive positive pressure ventilation
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Columbia University
Amyotrophic Lateral Sclerosis
Compassionate Treatment : An Exploratory Clinical Trial to Assess Treatment of Amyotrophic Lateral Sclerosis
The purpose of the study is to determine the safety and possible effectiveness of Autologous Adipose-Tissue Derived Stem Cells treatment in a Amyotrophic Lateral Sclerosis(ALS) patient.
- Trial name
- NCT02383654
- Testing
- Autologous Adipose-Tissue Derived Stem Cells
- Where
- Taiwan
- Volunteers
- 1 people
- Sponsor
- China Medical University Hospital
Amyotrophic Lateral Sclerosis
Effects of Gastrostomy on Amyotrophic Lateral Sclerosis
Results about effects of symptomatic treatment on QoL appears conflicting in ALS patients. Moreover no clear effects of gastrotomy have be shown on survival.
- Trial name
- NCT00337402
- Where
- France
- Volunteers
- 380 people
- Sponsor
- University Hospital, Clermont-Ferrand
Amyotrophic Lateral Sclerosis, ALS
Study of miRNA Expression Pattern as Diagnostic and Prognostic Biomarker in Amyotrophic Lateral Sclerosis
The principal goal is to demonstrate that a specific pattern of microRNA (miRNA) expression can be correlated with the definite diagnostic of Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- MIRSLA (NCT01992029)
- Testing
- Clinical evaluation, Muscular biopsy, Lumbar puncture
- Where
- France
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Amyotrophic Lateral Sclerosis
Optimizing INITIation of Non-invasive Ventilation in ALS Patients
Objective: The primary objective in this study is to identify which (pheno)type of ALS patient has the most benefit from NIV in improving quality of life.
- Trial name
- INITIALS (NCT05033951)
- Testing
- Standard care
- Where
- Netherlands
- Volunteers
- 250 people
- Sponsor
- University Medical Center Groningen
Amyotrophic Lateral Sclerosis
A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS
Arimoclomol is a small molecule that upregulates "molecular chaperones" in cells under stress. Arimoclomol extends survival by five weeks when given both pre-symptomatically and at disease onset in a mutant superoxide dismutase…
- Trial name
- NCT00561366
- Testing
- Arimoclomol
- Where
- 35 sites in United States, Canada
- Sponsor
- CytRx
Amyotrophic Lateral Sclerosis
Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS
Muscular cramps are a common and uncomfortable symptom of amyotrophic lateral sclerosis (ALS). This clinical trial will compare the response of high dose vitamin E supplementation to placebo for treatment of muscular cramps in…
- Trial name
- NCT00372879
- Testing
- Vitamin E
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Amyotrophic Lateral Sclerosis
Multidisciplinary Follow-up of Patients With Amyotrophic Lateral Sclerosis
Analyse a multidisciplinary follow-up of amyotrophic lateral sclerosis patients, monitored through a Cohort study at Geneva University Hospitals.
- Trial name
- NCT03536962
- Testing
- no intervention
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- Ruxandra Iancu Ferfoglia
Spinal Cord Injuries, Amyotrophic Lateral Sclerosis
Diaphragmatic Pacer Placement: Anesthetic Management (DP)
The diaphragmatic pacemaker (DP) has proven its utility in replacing mechanical ventilation (MV) in patients with chronic spinal cord injury (SCI) and Amyotrophic Lateral Sclerosis (ALS), by improving the patients quality of life…
- Conditions
- Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Respiratory Paralysis
- Trial name
- DP (NCT02942953)
- Testing
- Diaphragmatic Pacer
- Volunteers
- 16 people
- Sponsor
- Institut Guttmann
Amyotrophic Lateral Sclerosis
Neuromuscular Transmission in Amyotrophic Lateral Sclerosis
Consistent data suggest that neuromuscular transmission is impaired in ALS patients. Neuromuscular junctions dysfunction may appear very early in the disease, as shown by data in animal models.
- Trial name
- NETALS (NCT00847847)
- Testing
- Anconeus Muscle biopsy
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Amyotrophic Lateral Sclerosis
sCD163 in ALS Patients
Amyotrophic lateral sclerosis (ALS) is a fatal disease with progressive muscle weakness leading to severe disability and eventually death.Since the diagnosis relies on clinical features and electromyographic abnormalities, which…
- Trial name
- NCT02325375
- Testing
- lumbar puncture for spinal fluid and blood sample
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- University of Aarhus
Amyotrophic Lateral Sclerosis
Tongue Strength in Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease with a poor prognosis that occurs in adults 64 years on average. Its prevalence is 4 to 6/100 000 inhabitants.
- Trial name
- NCT02665663
- Testing
- medical device
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
ALS (Amyotrophic Lateral Sclerosis)
Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis
This clinical study is in participants with Amyotrophic Lateral Sclerosis and is designed to evaluate the safety and tolerability of the gene therapy CTx1000.
- Trial name
- KOANEWA (NCT07401121)
- Testing
- AAV9 Gene therapy
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- Celosia Therapeutics Pty Ltd
Amyotrophic Lateral Sclerosis
A Study of STRO4 in Patients Amyotrophic Lateral Sclerosis (ALS)
This study intends to evaluate the safety and efficacy of STR04 administered intravenously in participants with Amyotrophic Lateral Sclerosis.
- Trial name
- NCT06910384
- Testing
- STR04
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- New England Cell Therapeutics, Inc.
Amyotrophic Lateral Sclerosis (ALS)
Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)
This is a long-term, double-blind, placebo-controlled study of MCI-186 to treat ALS. This study is the long-term extension of Study NCT00330681; Study NCT00330681 is a Phase 3, randomized, double-blind, placebo control, parallel…
- Trial name
- NCT00424463
- Testing
- MCI-186
- Where
- Japan
- Volunteers
- 181 people
- Sponsor
- Shionogi
Amyotrophic Lateral Sclerosis
Efficacy and Safety of Nitrazine in the Treatment of ALS
To evaluate the trend of safety and effectiveness of Nitroketazine tablets for ALS patients, and to explore the best effective dose.
- Trial name
- NCT04950647
- Testing
- Nitrofurazone Group 1, Nitroketazine Group 2
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking University Third Hospital
Amyotrophic Lateral Sclerosis
Rapamycin Treatment for ALS
In the last years research has pointed out potential mechanisms of pathogenesis in ALS including lack of degradation of abnormally accumulated proteins inside motor neurons, and an unbalanced function of the immune system leading…
- Trial name
- RAP-ALS (NCT03359538)
- Testing
- Rapamycin
- Where
- 7 sites in Italy
- Volunteers
- 63 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena